In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life
暂无分享,去创建一个
D. Holtzman | S. Paul | J. Cirrito | K. Bales | R. Demattos | P. May | J. Audia | Mark A O'dell | J. Cramer | M. Parsadanian | Jennie W. Taylor | J. Nissen | Jennie W. Taylor | J. W. Taylor | Jennie W. Taylor | Maia Parsadanian | R. DeMattos
[1] Carl W. Cotman,et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.
[2] M. Staufenbiel,et al. Extracellular amyloid formation and associated pathology in neural grafts , 2003, Nature Neuroscience.
[3] R. Malinow,et al. APP Processing and Synaptic Function , 2003, Neuron.
[4] Matthew P. Frosch,et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[5] Lieve Dillen,et al. Characterization of amyloid β peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein , 2003 .
[6] Bruce J Aronow,et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[7] J. Kornhuber,et al. Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation , 2002, Journal of neurochemistry.
[8] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[9] D. Holtzman,et al. Plaque‐associated disruption of CSF and plasma amyloid‐β (Aβ) equilibrium in a mouse model of Alzheimer's disease , 2002, Journal of neurochemistry.
[10] D. Holtzman,et al. Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease , 2002, Science.
[11] Rong Wang,et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.
[12] David J. Cummins,et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[13] C. Masters,et al. Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice , 2001, Neuron.
[14] D. Selkoe. Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.
[15] D. Holtzman,et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.
[16] P. S. St George-Hyslop. Genetic Factors in the Genesis of Alzheimer's Disease , 2000, Annals of the New York Academy of Sciences.
[17] Thomas G. Cole,et al. Differences in the Aβ40/Aβ42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype , 2000 .
[18] S. Younkin,et al. Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer’s disease , 2000 .
[19] F. D. Miller,et al. Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain , 2000, Journal of neurochemistry.
[20] J R Ghilardi,et al. Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. , 2000, Biochemistry.
[21] V Hachinski,et al. Vascular Factors in Cognitive Impairment‐Where Are We Now? , 2000, Annals of the New York Academy of Sciences.
[22] A. Fagan,et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[23] T. Saido,et al. Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition , 2000, Nature Medicine.
[24] S. Sisodia. Alzheimer's disease: perspectives for the new millennium. , 1999, The Journal of clinical investigation.
[25] Dominic M. Walsh,et al. Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons , 1999, The Journal of Neuroscience.
[26] D. Selkoe,et al. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. , 1999, The Journal of biological chemistry.
[27] D L Price,et al. Genetic neurodegenerative diseases: the human illness and transgenic models. , 1998, Science.
[28] D. Teplow,et al. Structural and kinetic features of amyloid beta-protein fibrillogenesis. , 1998, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[29] T. Wisniewski,et al. Biology of Aβ Amyloid in Alzheimer's Disease , 1997, Neurobiology of Disease.
[30] R. Dodel,et al. α2‐Macroglobulin as a β‐Amyloid Peptide‐Binding Plasma Protein , 1997 .
[31] R. Martins,et al. Characterization of the Binding of Amyloid‐β Peptide to Cell Culture‐Derived Native Apolipoprotein E2, E3, and E4 Isoforms and to Isoforms from Human Plasma , 1997, Journal of neurochemistry.
[32] R. Tanzi,et al. REVIEWThe Gene Defects Responsible for Familial Alzheimer's Disease , 1996, Neurobiology of Disease.
[33] B. D. Anderson,et al. Quantitative assessment of blood-brain barrier damage during microdialysis. , 1996, The Journal of pharmacology and experimental therapeutics.
[34] L. Mucke,et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.
[35] D. Brems,et al. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. , 1994, Molecular pharmacology.
[36] G. Perry,et al. Identification and transport of full-length amyloid precursor proteins in rat peripheral nervous system , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[37] T. Wisniewski,et al. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. , 1993, The Biochemical journal.
[38] P. Knopf,et al. Drainage of Brain Extracellular Fluid into Blood and Deep Cervical Lymph and its Immunological Significance , 1992, Brain pathology.
[39] H. Vinters,et al. Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[40] J. B. Justice,et al. In vivo calibration of microdialysis probes for exogenous compounds. , 1992, Analytical chemistry.
[41] P F Morrison,et al. Quantitative Examination of Tissue Concentration Profiles Associated with Microdialysis , 1992, Journal of neurochemistry.
[42] H. Benveniste,et al. Microdialysis—Theory and application , 1990, Progress in Neurobiology.
[43] H. Benveniste. Brain Microdialysis , 1989, Journal of neurochemistry.
[44] A. Hamberger,et al. Mass transfer in brain dialysis devices—a new method for the estimation of extracellular amino acids concentration , 1985, Journal of Neuroscience Methods.
[45] E. Zhang,et al. Directional and compartmentalised drainage of interstitial fluid and cerebrospinal fluid from the rat brain , 2004, Acta Neuropathologica.
[46] D. Selkoe,et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[47] M. Mercken,et al. Characterization of amyloid beta peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein. , 2003, Journal of neurochemistry.
[48] D. Holtzman,et al. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. , 2002, Journal of neurochemistry.
[49] D. Holtzman,et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[50] D. Holtzman. Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy. , 2001, Journal of molecular neuroscience : MN.
[51] S. Younkin,et al. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. , 2000, Biochimica et biophysica acta.
[52] A. Fagan,et al. Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. , 2000, Annals of neurology.
[53] T. Wisniewski,et al. Biology of A beta amyloid in Alzheimer's disease. , 1997, Neurobiology of disease.
[54] S. Paul,et al. alpha2-Macroglobulin as a beta-amyloid peptide-binding plasma protein. , 1997, Journal of neurochemistry.
[55] S. Paul,et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. , 1997, Nature genetics.
[56] R. Motter,et al. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[57] R. Tanzi,et al. The gene defects responsible for familial Alzheimer's disease. , 1996, Neurobiology of disease.
[58] E. Matsubara,et al. Characterization of apolipoprotein J-Alzheimer's A beta interaction. , 1995, The Journal of biological chemistry.